Drug Database
AR

artemisinin (artemisinin, Mateon / ArtiShield / ARTIVeda)

✓ Approved

Oncotelic Therapeutics, Inc. · 治疗药物

什么是 artemisinin?

artemisinin 是一种治疗药物,由Oncotelic Therapeutics, Inc.研发。该药已获批,用于治疗相关适应症,给药途径:Oral (PO)。

药物档案

商品名artemisinin, Mateon, ArtiShield, ARTIVeda
公司Oncotelic Therapeutics, Inc.
给药途径Oral (PO)
状态Approved

治疗适应症

artemisinin 针对 6 个适应症,涉及 6 个治疗领域。

治疗领域疾病/病症分期
InvestigationsBody temperature increased✓ Approved
Hepatobiliary disordersHepatitis✓ Approved
General disorders and administration site conditionsPyrexia✓ Approved
Infections and infestationsCOVID-19Phase I
Respiratory, thoracic and mediastinal disordersAcute respiratory distress syndromePhase I

注册免费账户还可查看另外 1 个适应症

免费注册查看全部适应症 →

相关研究文献

PubMedCurrent medicinal chemistry2026-11-18

Dihydroartemisinin Suppresses Colorectal Cancer Growth in Association with JAK2/STAT3 Signalling Modulation.

Huang Ju J, Zhang Yukun Y, Luo Jun J, Shi Zhengda Z et al.

Dihydroartemisinin (DHA), an active derivative of artemisinin, has anti-tumour potential, but its immunomodulatory effects in Colorectal Cancer (CRC) remain insufficiently defined. We investigated whether DHA suppresses CRC phenotypes in association with JAK2/STAT3 inhibition and altered immune-checkpoint- marker expression. HCT116 and RKO CRC cells were evaluated using CCK-8, colony formation, wound healing, Transwell migration, live/dead staining, qRT-PCR, western blotting, and pharmacological rescue assays. A total of 20 male C57BL/6 mice (6-8 weeks old; 22-25 grams) with AOM/DSS-induced CRC were allocated to control and DHA-treatment groups (n = 10 per group) to assess tumour burden, pathway-associated markers, checkpoint-marker expression and CD8+ cell presence in tumour tissue. DHA inhibited CRC cell proliferation and migration and promoted apoptosis, as indicated by reduced Bcl-2 and increased cleaved caspase-3. DHA reduced JAK2/STAT3 signalling and PD-L1/CD47 expression; these effects were partly counteracted by Coumermycin A1. in vivo, DHA reduced tumour burden, improved histological differentiation, reduced Ki-67, JAK2/STAT3, PD-L1 and CD47 staining, and was associated with increased intratumoural CD8+ cell staining. The findings support an association between DHA treatment and reduced JAK2/STAT3 signalling, lower immune-evasion marker expression, and increased CD8+ cell presence; functional activation of CD8+ cells was not directly assessed. DHA suppresses CRC progression in the models studied and modulates JAK2/STAT3-associated immune-evasion markers. These data support further preclinical evaluation of DHA as a potential adjunctive strategy for CRC.

PMID 43048835
阅读全文 →
PubMedJournal of nanobiotechnology2026-11-17

Tumor-Targeting monodisperse hydroxyapatite core-shell nanospheres for overcoming multidrug resistance in cancer therapy via tumor-specific synergistic calcium overload.

Zhang Shuiquan S, Shen Tao T, Zhang Wen W, Gong Xue X et al.

Multidrug resistance (MDR) remains a central obstacle in cancer therapy, accounting for over 90% of cancer-related mortality. Although calcium overload has emerged as a promising anticancer strategy, its clinical translation is largely limited by insufficient tumor selectivity. Hydroxyapatite nanoparticles (HAPNs) possess intrinsic biocompatibility and the ability to induce tumor-specific Ca2+ overload; however, conventional synthesis methods often yield polydisperse and aggregation-prone particles, resulting in high dosage requirements and inconsistent antitumor efficacy. Herein, we reported a tumor-targeting monodisperse hydroxyapatite core-shell nanospheres (TMHCNs) fabricated via microfluidic coaxial chips (MCC)-assisted soft-templating strategy to achieve precise physicochemical control for tumor-specific synergistic Ca2+ overload therapy. FDA-approved components, sebacic acid, glycerol, and polyethylene glycol, were used to compose uniform nanomicelles as soft templates for homogeneous mineralization, enabling reproducible generation of uniform core-shell nanospheres. Subsequent surface functionalization with hyaluronic acid (HA) yielded monodisperse tumor-targeting nanospheres, TMHCNs (47.0 ± 5.0 nm) with enhanced CD44-mediated cellular uptake. The antimalarial drug and sarcoplasmic/endoplasmic reticulum Ca2+-ATPase (SERCA) inhibitor, artemisinin (Art), was then selected and encapsulated into TMHCNs to construct the synergistic Ca2+ overload nanosystem Art@TMHCNs. TMHCNs alone induced sustained and tumor-selective intracellular Ca2+ overload. Loading the SERCA inhibitor Art further amplified tumor-specific Ca2+ overload, triggered mitochondrial dysfunction, depleted ATP, and activated both intrinsic and extrinsic apoptotic pathways, thereby effectively reversing MDR. In an A549/PTX xenograft model, Art@TMHCNs achieved complete tumor growth suppression and pronounced tumor-specific calcification with minimal off-target toxicity. This work establishes a precisely engineered, monodisperse hydroxyapatite core-shell platform that amplifies tumor-specific calcium dysregulation and provides a clinically translatable strategy for safe and effective MDR reversal in cancer therapy.

PMID 43040504
阅读全文 →
PubMedFrontiers in cellular and infection microbiology2026-11-17

Molecular surveillance of drug resistance markers in Plasmodium falciparum isolates from Ghana.

Myers-Hansen James L JL, Broyles Bradley B, Schwabl Philipp P, Mensah Benedicta A BA et al.

The emergence and spread of Plasmodium falciparum drug-resistant parasites remain a significant hurdle to malaria control and elimination. However, how changes in transmission affect the evolution of drug resistance remains incompletely understood. We investigated the spatiotemporal prevalence of drug resistance across three distinct eco-epidemiological zones of Ghana (Guinea Savannah, Forest and Coastal) by characterizing genetic polymorphisms in five drug resistance genes (pfdhfr, pfdhps, pfmdr1, pfk13 and pfmdr2). A total of 764 P. falciparum isolates collected between 2010 and 2017 were analyzed using amplicon sequencing. The artemether lumefantrine (AL) resistance-associated genotypes, pfmdr1-N86 and pfmdr1-N86 F 184D1246, were near fixation in the Forest zone (90-100% and 63.9-100%, respectively). The prevalence of pfmdr1-N86 also increased significantly over time in the Guinea Savannah and Coastal zones (χ2 = 7.13, P<0.05; χ2 = 7.19, P<0.05). Regarding artemisinin (ART) resistance, none of the validated Southeast Asian pfk13 mutations were detected. We also characterized mutations in pfmdr2, another ART resistance-associated gene, for the first time in the Savannah and Forest zones of Ghana. For sulphadoxine-pyrimethamine (SP) resistance, the resistance-conferring alleles pfdhps - 540E and pfdhps - 581G occurred at prevalences below 5% and 10%, respectively. Similarly, the pfdhfr/pfdhps-I51R59N108G437E540 haplotype, associated with full SP resistance, was detected in fewer than 5% of parasites. The observed resurgence of parasites carrying the chloroquine (CQ)-sensitive proxy marker pfmdr1-N86, together with the increase in CQ-wildtype marker (pfcrt-K76) prevalence reported in other studies, suggests that CQ sensitivity is re-emerging and may inform future consideration of CQ-based combination therapies. Additionally, the rarity of the pfdhfr/pfdhps-I51R59N108G437E540 and pfdhfr/pfdhps-I51R59N108G437E540G581 haplotypes, driven by the low prevalence of pfdhps - 540E and pfdhps - 581G alleles, supports the continued use of SP for preventive therapy in Ghana.

PMID 43041397
阅读全文 →
PubMedmBio2026-11-16

Characterizing malaria parasite drug response using single-cell transcriptomics.

Godinez-Macias Karla P KP, Calla Jaeson J, Jepsen Kristen K, Winzeler Elizabeth A EA

Gene expression analysis in malaria parasites has been used to define transcriptional regulatory networks but has been used less frequently to characterize parasite response to drug treatment or to show how parasites may evade killing. Here, we applied single-cell RNA sequencing (scRNA-seq) to hundreds of thousands of individually infected asynchronous red blood cells to evaluate the parasite's response to treatment with three chemotypes that can be used for treatment (artemisinin) or prophylaxis and treatment (atovaquone and ganaplacide). We found that each treatment gave rise to different cell populations with different transcriptional profiles. Comparing single-cell transcription patterns in compound-treated cells to transcript patterns observed previously with synchronized cells showed an enrichment of cells expressing gametocyte-associated genes after artemisinin treatment but fewer life cycle perturbations after treatment with the two other compounds. In contrast, bulk analysis showed an enrichment of pyrimidine biosynthesis transcripts for atovaquone treatment. Our results show that scRNA-seq may be used to profile diverse drug responses across many life cycle stages and to potentially classify drug classes.IMPORTANCEDetermining the mechanism of action (MOA) of compounds with antimalarial activity remains a key activity in both drug development and drug resistance studies but remains challenging for some chemotypes. Here we highlight the potential of single-cell transcriptional sequencing to augment the process of MOA deconvolution. We develop a new analytical pipeline that involves comparing single-cell transcription patterns to existing profiles from synchronized parasites to comprehensively characterize life cycle stage enrichments that may be observed after chemical perturbations. We also show that transcriptional feedback regulation may be present for some drug classes.

PMID 43037396
阅读全文 →
PubMedChemMedChem2026-11-16

Artesunate Derivatives as Anticancer Agents: Hybrid Designs and Emerging Therapeutic Strategies.

Selaković Milica M, Koračak Ljiljana L, Ajdačić Vladimir V, Nikolić Andrea M AM et al.

Artesunate is a semisynthetic derivative of the natural product artemisinin, isolated from Artemisia annua and characterized by the biologically important endoperoxide bridge. Beyond its established use in malaria treatment, in recent decades, artesunate has attracted growing research interest as an anticancer agent. Despite encouraging preclinical results, clinical studies demonstrated only modest efficacy when artesunate was used as a single compound, due to its low bioavailability, toxicity, and unfavorable side effects. For this reason, artesunate derivatization has attracted significant attention, as the resulting derivatives often exhibit superior anticancer activity in both in vitro and in vivo studies compared with artesunate alone. This review offers a comprehensive overview of reported artesunate derivatives, structured into sections based on the type of molecule employed for derivatization and highlights the expanding research on their anticancer activity. Currently emerging strategies that include hybridization and nanocarrier-based delivery systems which may accelerate the clinical translation of artesunate derivatives and harness their potential in anticancer drug discovery are also discussed. While significant progress has been made, a lot of the research field still remains underexplored.

PMID 43039867
阅读全文 →
PubMedEuropean journal of immunology2026-11-16

Dihydroartemisinin Acetal Dimer Suppresses Th1/Th17-Mediated Pro-Inflammatory Axis to Mitigate EAE.

Lv Jie J, Wan Gen G, Luo Jing J, Jiang Xiangrui X et al.

Multiple sclerosis (MS) is a central nervous system (CNS)-specific chronic disorder, characterized by T cell-mediated demyelination and neuroinflammation. Dihydroartemisinin, a semisynthetic artemisinin derivative, has been reported as a potential MS treatment for its immunomodulatory activity. This work investigated dihydroartemisinin acetal dimer (DHAAD), a novel dihydroartemisinin derivative, for MS therapy and explored possible mechanistic insights. A library of 14 small-molecule compounds was screened through in vitro Th1/Th17 differentiation assays. Experimental autoimmune encephalomyelitis (EAE), an animal model for MS, was induced in mice with the MOG35 - 55 peptide. The compound identified through screening was orally administered to mice at various doses. Its therapeutic effects at the tissue and cellular levels were assessed using histopathological analysis and flow cytometry, respectively, while the effects on cytokine levels and signature gene expression were evaluated through enzyme-linked immunosorbent assay and quantitative polymerase chain reaction, respectively. DHAAD was identified as effectively inhibiting Th1/Th17 cell differentiation. DHAAD treatment mitigated EAE manifestations in mice (reduced clinical scores, leukocyte infiltration, and CNS demyelination) and suppressed Th1/Th17 cell populations in both CNS and peripheral compartments, concurrently reducing IFN-γ and IL-17A secretion. Upon MOG35 - 55 re-stimulation, splenocytes and lymph node cells from treated mice also exhibited decreased IFN-γ and IL-17A production. Furthermore, DHAAD administration downregulated the genes driving Th1/Th17 cell differentiation and those executing their pro-inflammatory functions. DHAAD alleviates EAE symptoms by suppressing pro-inflammatory Th1/Th17 differentiation pathways through its immunosuppressive effects in the CNS and peripheral sites, thereby ameliorating inflammation and revealing its application potential in MS.

PMID 43036947
阅读全文 →

注册免费账户还可查看另外 8884 篇文献

免费注册查看全部文献 →

了解更多artemisinin